Get the Stockscreener App
1.09
2.83%
0.03
Alterity Therapeutics Ltd Adr Stock (ATHE) Latest News
Alterity Therapeutics reports annual general meeting results By Investing.com - Investing.com South Africa
Alterity Therapeutics reports annual general meeting results - Investing.com India
Alterity Therapeutics announces change in company secretary - Investing.com
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Yahoo Finance
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics announces change in share registry - Investing.com
Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK
Opthea Ltd stock soars to 52-week high, hits $4.47 - Investing.com India
Alterity Therapeutics names new CFO - Investing.com India
Alterity Therapeutics discloses annual report for 2024 - Investing.com
Alterity Therapeutics announces regulatory notice filing - Investing.com
ATHE’s Stock Market Adventure: -14.26% YTD Growth Amidst Volatility - The InvestChronicle
Alterity reports positive Phase 2 trial interim data - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alphabet stock cited by TD Cowen amid potential Wiz acquisition - Investing.com
Alterity Therapeutics announces trading halt By Investing.com - Investing.com
Avenue Supermarts stock target raised by Nuvama, still a Hold - Investing.com India
Wolfe Research keeps Peerperform rating on Goldman Sachs stock, notes mixed Q2 earnings - Investing.com India
RBC Capital sees growth potential in Bowhead Specialty shares - Investing.com
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
ASX Health Winners December: Health stocks beat market, look ‘undervalued’ going into 2024 - Stockhead
Closing Bell: The ASX is slightly higher, but not much cooler on Monday - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
Check up: Enthusiasm rather than news is moving health stocks - Stockhead
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For An - Benzinga
54 Biggest Movers From YesterdayAcasti Pharma (NASDAQ:ACST), Alterity Therapeutics (NASDAQ:ATHE) - Benzinga
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):